Methods for promoting organ development
AssigneeKintan Pty Ltd.
InventorsSharon Denise Ricardo, David Arthur Hume, Melissa Helen Little, Christina Victoria Jones
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for promoting organ development in warm blooded animals, and in particular in certain aspects a premature infant or foetus. Compositions and methods are also provided for the administration of at least one colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof, or otherwise, at least one nucleic acid molecule encoding colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof.
Claims17
A method of treating reduced renal function in an infant or fetus in need thereof, comprising:
- administering to the infant or fetus a therapeutically effective amount of a pharmaceutical composition comprising colony stimulating factor-1 protein (CSF-1), or a precursor, variant, isoform, analogue, or derivative thereof;
- wherein:
- i) the precursor, variant, isoform, analogue, or derivative of CSF-1 has retained substantial similarity in biological function to CSF-1 and comprises the C-terminal fragment of CSF-1, comprising the C-terminal 150 amino acids of the 536 amino acid CSF-1 protein;
- and
- ii) the treated infant or fetus has an improvement in renal function, comprising a promotion in kidney development, an increase in kidney weight or volume, an increase in kidney growth, an increase in nephrogenesis, an increase in the number of nephrons, enhanced nephrogenesis, or kidney maturation.
A method of treating an infant or fetus having an underdeveloped kidney, comprising:
- administering to the infant or fetus a therapeutically effective amount of a pharmaceutical composition comprising colony stimulating factor-1 protein (CSF-1), or a precursor, variant, isoform, analogue, or derivative thereof;
- wherein:
- i) the precursor, variant, isoform, analogue, or derivative of CSF-1 has retained substantial similarity in biological function to CSF-1 and comprises the C-terminal fragment of CSF-1, comprising the C-terminal 150 amino acids of the 536 amino acid CSF-1 protein;
- and
- ii) the treated infant or fetus has a promotion in kidney development, comprising an increase in renal function, an increase in kidney weight or volume, an increase in kidney growth, an increase in nephrogenesis, an increase in the number of nephrons, enhanced nephrogenesis, or kidney maturation.
Dependencies are inferred from the claim text.